Point72 Asset Management
SUPN icon

Point72 Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Point72 Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58,900
Closed -$2.97M – 1190
2018
Q3 		$2.97M Sell
58,900
-291,100
-83% -$14.4M 0.01% 694
2018
Q2 		$20.9M Buy
+350,000
New +$18.1M 0.08% 292

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's SUPN Position: Q1 2026 in Review

Point72 Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 42% in Q1 2026, selling an estimated $48.2M and leaving 1,318,555 shares worth $68.2M. The position accounts for 0.09% of the portfolio, ranked #269.

Point72 Asset Management first reported a position in SUPN in Q1 2016 and has held it in 13 quarters since. The position peaked at $113M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Point72 Asset Management held 1,318,555 shares of Supernus Pharmaceuticals worth $68.2M as of Q1 2026.
  • Point72 Asset Management sold 946,245 Supernus Pharmaceuticals shares in Q1 2026, an estimated $48.2M.
  • Supernus Pharmaceuticals made up 0.09% of Point72 Asset Management's portfolio in Q1 2026, its #269 holding.
  • Point72 Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2016 and has held it in 13 quarters since.
  • Point72 Asset Management's Supernus Pharmaceuticals position peaked at $113M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.